As both US and EU antitrust regulators discuss the fight against pay-for-delay agreements, seen as anticompetitive for the pharmaceuticals market, the European Commission is reporting an increased number of cases against brand name drug makers concerning the agreements. At the Reuters Euro Zone Summit, Commissioner Joaquin Almunia announced additional cases are headed towards the regulator as more than a dozen drug companies have already been under fire and encompassed under four investigations by the Commission. In outlining the Commissions’ plan of attack to combat the anticompetitive actions, which could lead to consumers paying more for drugs as generics are kept off the shelves, Almunia noted that while those who hold patents to a drug must be protected, once those patents expire, “all citizens should have the right” to access the generics and, therefore, cheaper drugs. The companies involved in the ongoing investigations were not named at the Summit.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI